Logo image
Back
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
Journal article   Open access   Peer reviewed

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies

Christopher T. Ritchlin, Philip J. Mease, Wolf-Henning Boehncke, John Tesser, Elena Schiopu, Soumya D. Chakravarty, Alexa P. Kollmeier, Xie L. Xu, May Shawi, Yusang Jiang, …
Rheumatic & musculoskeletal diseases open, v 8(1), pe002195
01 Mar 2022
DOI: https://doi.org/10.1136/rmdopen-2022-002195
PMID: 35296534
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1136/rmdopen-2022-002195View
Published, Version of Record (VoR)CC BY-NC V4.0,  Open

Abstract

Life Sciences & Biomedicine Rheumatology Science & Technology
Objectives To evaluate the efficacy through 52 weeks of guselkumab, an interleukin 23-p19 subunit inhibitor, in subgroups of pooled psoriatic arthritis (PsA) patients from the DISCOVER-1 and DISCOVER-2 trials defined by baseline patient characteristics. Methods Adults with active PsA despite standard therapies were enrolled in DISCOVER-1 (>= 3 swollen and >= 3 tender joints, C reactive protein (CRP) level >= 0.3 mg/ dL) and DISCOVER-2 (>= 5 swollen and >= 5 tender joints, CRP >= 0.6 mg/dL, biological-naive). Randomised patients received 100 mg guselkumab at weeks 0, 4, and then every 4 or 8 weeks (Q4W/Q8W) or placebo. Guselkumab effects on joint (ACR20/50/70), skin (IGA 0/1, IGA 0), patient-reported outcome (Health Assessment Questionnaire Disability Index/Functional Assessment of Chronic Illness Therapy-Fatigue) and disease severity (minimal disease activity/PsA Disease Activity Score low disease activity) endpoints were evaluated by patient sex, body mass index, PsA duration, swollen/tender joint counts, CRP level, percent body surface area with psoriasis, Psoriasis Area and Severity Index score, and conventional synthetic disease-modifying antirheumatic drug use at baseline. Results Baseline patients characteristics in DISCOVER-1 (N=381) and DISCOVER-2 (N=739) were well balanced across randomised groups. At week 24, 62% (232/373) and 60% (225/375), respectively, of guselkumab Q4W-treated and Q8W-treated patients pooled across DISCOVER-1 and DISCOVER-2 achieved the primary endpoint of ACR20 response versus 29% (109/372) of placebo-treated patients. Guselkumab treatment effect at week 24 was observed across patient subgroups. Within each patient subgroup, response rates across all disease domains were sustained or increased at week 52 with both guselkumab regimens. Conclusions Guselkumab Q4W and Q8W resulted in robust and sustained improvements in PsA signs and symptoms consistently in subgroups of patients defined by diverse baseline characteristics.

Metrics

15 Record Views
32 citations in Web of Science
22 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Web of Science research areas
Rheumatology
Logo image